Literature DB >> 19907945

Stimulating platelet production to raise platelet count in immune thrombocytopenic purpura: A novel approach.

Jagdish Chandra1, V P Choudhry.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19907945     DOI： 10.1007/s12098-009-0206-y

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN： 0019-5456            Impact factor:   1.967


× No keyword cloud information.
  13 in total

Review 1.  How I treat idiopathic thrombocytopenic purpura (ITP).

Authors:  Douglas B Cines; James B Bussel
Journal:  Blood       Date:  2005-06-07       Impact factor: 22.113

2.  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

Authors:  James B Bussel; David J Kuter; James N George; Robert McMillan; Louis M Aledort; George T Conklin; Alan E Lichtin; Roger M Lyons; Jorge Nieva; Jeffrey S Wasser; Israel Wiznitzer; Reggie Kelly; Chien-Feng Chen; Janet L Nichol
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

3.  Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Authors:  J Li; C Yang; Y Xia; A Bertino; J Glaspy; M Roberts; D J Kuter
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

4.  An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.

Authors:  Adrian Newland; Marie T Caulier; Mies Kappers-Klunne; Martin R Schipperus; Francois Lefrere; Jaap J Zwaginga; Jenny Christal; Chien-Feng Chen; Janet L Nichol
Journal:  Br J Haematol       Date:  2006-11       Impact factor: 6.998

5.  Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

Authors:  Russell L Basser; Elizabeth O'Flaherty; Michael Green; Maria Edmonds; Janet Nichol; Dora M Menchaca; Brian Cohen; C Glenn Begley
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

6.  Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

Authors:  James B Bussel; Drew Provan; Tahir Shamsi; Gregory Cheng; Bethan Psaila; Lidia Kovaleva; Abdulgabar Salama; Julian M Jenkins; Debasish Roychowdhury; Bhabita Mayer; Nicole Stone; Michael Arning
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

7.  Assay of an activity in the serum of patients with disorders of thrombopoiesis that stimulates formation of megakaryocytic colonies.

Authors:  R Hoffman; E Mazur; E Bruno; V Floyd
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

8.  Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura.

Authors:  Shosaku Nomura; Kazuo Dan; Tomomitsu Hotta; Kingo Fujimura; Yasuo Ikeda
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials.

Authors:  James N George; Susan D Mathias; Ronald S Go; Matthew Guo; David H Henry; Roger Lyons; Robert L Redner; Lawrence Rice; Martin R Schipperus
Journal:  Br J Haematol       Date:  2008-11-11       Impact factor: 6.998

10.  Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.

Authors:  James B Bussel; Gregory Cheng; Mansoor N Saleh; Bethan Psaila; Lidia Kovaleva; Balkis Meddeb; Janusz Kloczko; Habib Hassani; Bhabita Mayer; Nicole L Stone; Michael Arning; Drew Provan; Julian M Jenkins
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.